## Luck et al. [54] NON-ANTIGENIC COLLAGEN AND ARTICLES OF MANUFACTURE [76] Inventors: Edward E. Luck, 216 Robin Way, Menlo Park, Calif. 94025; John R. Daniels, 842 Las Casas, Pacific Palisades, Calif. 90272 [21] Appl. No.: 532,572 [22] Filed: Sep. 15, 1983 Related U.S. Application Data Continuation-in-part of Ser. No. 144,705, Apr. 28, [60] 1980, now Defensive Publication No. Int. Cl.<sup>3</sup> ...... C08L 89/06; C07G 7/00 [52] U.S. Cl. ...... 106/161; 204/158; 210/637; 210/644; 210/645; 260/123.7; 106/161, 155; 210/637, 644, 645; 204/158; 264/202 [56] References Cited U.S. PATENT DOCUMENTS 2,919,999 1/1960 Reissman et al. ...... 106/161

2,920,000 1/1960 Hochstadt et al. ...... 106/161

3,131,130 4/1964 Oneson et al. ...... 106/161

3,303,038 2/1967 Klevens ...... 106/155

3,503,877 3/1970 Berry ...... 210/644

3,949,073 4/1976 Daniels et al. ...... 424/177

4,233,360 11/1980 Luck et al. ..... 106/155

3,314,861

United States Patent [19]

[11] Patent Number:

4,488,911

[45] Date of Patent:

Dec. 18, 1984

## FOREIGN PATENT DOCUMENTS

903975 4/1960 United Kingdom .

Primary Examiner—Theodore Morris

ABSTRACT

Collagen, available from domestic animals, is freed of noncollagen proteins, glycosaminoglycans and lipids by enzymatic treatment with a proteolytic enzyme to yield a product which is soluble in dilute acidic aqueous solutions (collagen in solution—CIS). The naturally occurring collagen is modified by removal of certain terminal peptide chains, which are described as telopeptides. The modified collagen, so derived, is described as atelopeptide collagen. Native collagen is immunogenic, while atelopeptide collagen is nonimmunogenic or possessed of a negligibly low level of immunogenicity.

The collagen in solution is then treated according to a specific regimen under conditions whereby the collagen slowly separates from solution while exposed to mild shear forces. This procedure results in the formation of a fibrous precipitate composed of regularly ordered fibers of collagen possessed of a rope-like structure. These resulting aggregates are referred to as native fibrous micropolymers (NFM). Once the regimen or procedure is completed, and the fiber mass has been formed, the fibrous micropolymers may be freed of salt, taken up in a different solution or modified. For example, cross-links may then be introduced to stabilize the fibers. The products find wide use as packing, membranes, fibers, bags, supports, integuments, and are especially suitable for biologic implantation or application.

14 Claims, No Drawings